Important limitations
- Individual claims and source links have not yet completed editorial verification.
- Evidence level, applicable study model, formulation, route and population remain unassigned.
Dosing & scaling, explained
The moderated mass amounts below are retained for comparison. Near-duplicates, mix-dependent volumes and device markings are excluded. This is educational source context, not a protocol or recommendation.
Mass amounts available for comparison
- Lower range200 mcgDose Strategy A
Recorded example with no verified study backing; shown for amount literacy only.
- Low-mid range400 mcgDose Strategy A
Recorded example with no verified study backing; shown for amount literacy only.
- Mid range1 mgTotal Weekly Range
Recorded example with no verified study backing; shown for amount literacy only.
Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.
No independently verified schedule
Evidence context
No clinical amount or schedule is inferred from this material. Source verification is pending, and every displayed amount remains educational context rather than guidance.
Storage, handling and interpretation
Product identity
Verify the exact compound, formulation and amount against the product label or certificate before calculation.
Storage & handling
Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.
Prepared solutions
Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.
Reported protocols for CJC-1295 DAC
What published studies and recent community write-ups report about amounts, timing and course length. 4 clinical, 1 preclinical and 4 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Clinical4 rows | |||||
| Phase 1 single ascending dose trialHealthy adults aged 21-61 (35 on active drug, 7 on placebo) | 30, 60, 125 or 250 mcg/kg | Single injection | Subcutaneous | One dose with 28 days of follow-upNot applicable | Journal of Clinical Endocrinology and Metabolism (PubMed)2006 |
| Mean GH rose 2- to 10-fold for 6 days or more and IGF-1 1.5- to 3-fold for 9-11 days, with IGF-1 leaving the age-adjusted normal range only at 250 mcg/kg; the half-life was 5.8-8.1 days. Injection-site reactions occurred in about 70% of treated subjects and loose stools, flushing and headache were dose-related, two subjects withdrew because of injection-site reactions, and no serious adverse reactions were recorded. | |||||
| Phase 1 multiple dose trial24 healthy adults in four cohorts (20 on active drug, 4 on placebo) | 20 or 30 mcg/kg weekly; 30 or 60 mcg/kg every two weeks | Three weekly injections (days 0, 7 and 14) or two biweekly injections (days 0 and 14) | Subcutaneous | 2 weeks of dosing with follow-up to day 49Not applicable | Journal of Clinical Endocrinology and Metabolism (PubMed)2006 |
| IGF-1 stayed above baseline through day 28 and peak drug concentrations were 29-70% higher after the day 14 injection than after the first, which the authors read as accumulation and pituitary priming and as grounds for a minimum 7-day interval. Every treated subject had injection-site reactions, flushing occurred in 40% at the low dose and 100% at the high dose, and one subject had transient involuntary leg contractions after the second 30 mcg/kg dose. | |||||
| GH pulsatility studyHealthy men aged 20-40 | 60 or 90 mcg/kg | Single injection | Subcutaneous | One dose, with 12-hour overnight sampling every 20 minutes before and one week afterNot applicable | Journal of Clinical Endocrinology and Metabolism (PubMed)2006 |
| A week after the injection, trough GH was 7.5 times higher, mean GH 46% higher and IGF-1 45% higher, while the number and size of GH pulses were unchanged. The two doses did not differ, and the IGF-1 rise did not correlate with any pulse parameter, which the authors took to mean that the raised baseline rather than the pulses drives IGF-1. | |||||
| 2026 review contrasting trial doses with forum protocolsHealthy-adult phase 1 data set against bodybuilding forum practice | 30 or 60 mcg/kg in the trials; 1-2 mg per week in forum protocols | Trials: 2-3 injections weekly or biweekly; forums: 1-2 injections per week | Subcutaneous | Forums: 8-12 or 12-16 weeks onForums: 4-6 weeks off | Frontiers in Endocrinology (PubMed Central)2026 |
| An endocrinology department's 2026 narrative review grades CJC-1295 DAC as tier B evidence: phase 1 pharmacokinetic and pharmacodynamic data in healthy adults with no controlled efficacy data and no long-term safety data. It tabulates the forum pattern of 1-2 mg a week in cycles of 8-16 weeks beside the trial doses and treats body-composition benefits as theoretical extensions of GH physiology. | |||||
| Preclinical1 row | |||||
| GHRH knockout mouse growth studyGHRH knockout mice treated from 1 week of age | 2 mcg per mouse | Every 24, 48 or 72 hours | Injection (route not stated in the abstract) | 5 weeksNot applicable | American Journal of Physiology, Endocrinology and Metabolism (PubMed)2006 |
| Daily 2 mcg doses normalized body weight, body length, femur and tibia length and body composition in mice that cannot make GHRH, while dosing every 48 or 72 hours produced only partial growth. Pituitary GH mRNA and total RNA rose, which the Johns Hopkins group read as somatotroph proliferation; the mice are a model of complete GHRH deficiency, not of healthy adults. | |||||
| Community-reported4 rows | |||||
| Community loading and steady-state schedule | 1 mg per week to load, then 1-2 mg per week | Once weekly, or the weekly amount split into 2 injections | Subcutaneous (2 mg vial in 2 mL of bacteriostatic water gives 1 mg/mL) | 8-12 weeks4-8 weeks off | Community resource2026 |
| A 2026 calculator site describes a two-week loading period at 1 mg a week to build the albumin-bound reservoir, then 1-2 mg a week to week 12, and says the peptide accumulates toward a plateau over 3-4 weeks. It attributes the 8-12 week cycle to avoiding receptor downregulation, a concern no human study of this compound has measured. | |||||
| Stepped weekly schedule from a 10 mg vial | 500-1,000 mcg weekly (weeks 1-2), 1,000 mcg weekly (weeks 3-8), up to 2,000 mcg weekly or 1 mg twice weekly (weeks 3-12) | Once weekly, sometimes split Monday and Thursday | Subcutaneous, evening; 10 mg vial in 3 mL of bacteriostatic water (about 3,333 mcg/mL) | 8-12 weeks standard; 12-16 weeks extended4-6 weeks off (6-8 weeks after an extended cycle) | Community resource2026 |
| This 2026 protocol page starts at 0.5-1 mg a week because side effects of a drug with a 6-8 day half-life persist for days, moves to 1 mg a week as the common maintenance figure and lists 2 mg a week as the elevated option. It states that the halted phase 2 trial used weight-based dosing far above these amounts, a figure that cannot be checked because the registry entry never posted its doses. | |||||
| Standard once- or twice-weekly protocol | 1,000-2,000 mcg (1-2 mg) | Once or twice weekly | Subcutaneous, any time of day (evening preferred by many) | Open-ended; the page's timeline runs to month 3 and beyondNone described | Community resource2026 |
| A dosing-calculator site gives 1 mg a week for general use and 2 mg a week where a faster IGF-1 rise is wanted, and says timing barely matters because of the long half-life. It warns that the trial percentages describe ConjuChem's trial material rather than a 2 mg research vial, that the drug is prohibited in sport under WADA S2, and that GH-axis stimulation can raise blood glucose. | |||||
| Weekly or fortnightly fixed dose versus the weight-based trial doses | 1,000-2,000 mcg | Once weekly or once every two weeks | Subcutaneous, abdomen or lateral thigh | Not established; the page calls cycle duration unstudiedNot established | Community resource2026 |
| A 2026 editorial page points out that fixed 1-2 mg doses are a pragmatic extrapolation and that the only human dose data are weight-based, working out 60 mcg/kg to 4.8 mg for an 80 kg adult. The 60-90 mcg/kg figures it attributes to the 2006 dose-escalation trial are in fact the doses of the separate pulsatility study, and no trial has compared any fixed weekly dose against another. | |||||
How a course is commonly described
- Weeks 1-2: loadingCommunity-reported
Community schedules open at 0.5-1 mg once a week, described as building the albumin-bound reservoir, with effects called subtle. In the phase 1 trials a single injection raised GH within an hour and IGF-1 within 8 hours, and both stayed up for roughly two weeks.
- Weeks 3-4: accumulationClinical
Guides describe a plateau forming over 3-4 weeks. The multiple-dose trial supports accumulation in principle: after the third weekly injection, peak drug levels were 29-70% higher than after the first and IGF-1 had not returned to baseline between doses, which is why the authors proposed a 7-day minimum interval.
- Weeks 5-12: maintenanceCommunity-reported
Maintenance is described at 1 mg a week, or 2 mg a week either as one injection or split into two, held to week 8-12 and sometimes to week 16. No trial dosed for longer than two weeks, so nothing in the published record describes what this phase does.
- BreakCommunity-reported
A 4-8 week off period follows, justified by a presumed need to let the pituitary axis reset. Because the drug stays albumin-bound for days, exposure tails off for one to two weeks after the last injection regardless of the schedule.
- Clinical comparisonClinical
The only multi-week human exposure ever planned was the phase 2 trial in HIV-associated visceral obesity: 12 weeks of low- or high-dose CJC-1295 against placebo with a 6-week follow-up in 120 patients. It was terminated in 2006 without posting doses or results, so no human data exist beyond three injections over two weeks.
- A fixed 1-2 mg weekly dose works out to roughly 12-25 mcg/kg for an 80 kg adult, at or below the 20-60 mcg/kg repeated doses used in the phase 1 trial, but those trials gave at most three injections over two weeks; nobody has published what months of weekly dosing do to GH, IGF-1, glucose or anything else.
- CJC-1295 was never approved by any regulator, its only efficacy trial was terminated, and no body-composition outcome has been measured in humans. It is prohibited in sport as a GH-releasing factor under the WADA list.
- A product sold as CJC-1295 analysed by a doping laboratory turned out to be the 29-residue amidated peptide without the Drug Affinity Complex, which clears in minutes rather than days, so a weekly schedule applied to a mislabelled vial produces a different exposure from the one described above.
Sources for this section (11)
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
- The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration
- A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity (NCT00267527)
- Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog
- Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse
- Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation
Plus 4 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.
Overview
CJC-1295 is a synthetic 30-residue analog of growth hormone-releasing hormone(1-29) developed by ConjuChem in Montreal: four substitutions (D-Ala2, Gln8, Ala15, Leu27) protect it from the enzyme DPP-IV, and a C-terminal lysine carries a maleimidopropionyl group, the Drug Affinity Complex, that bonds to cysteine 34 of serum albumin after injection and stretches the half-life from minutes to 5.8-8.1 days. In two phase 1 trials published in 2006, single and repeated subcutaneous doses of 20-250 mcg/kg in healthy adults raised growth hormone 2- to 10-fold for about 6 days and IGF-1 1.5- to 3-fold for 9-11 days while preserving GH pulses; a 2005-2006 phase 2 trial in HIV-associated visceral obesity was terminated and ConjuChem stopped development, so it was never approved anywhere. It is prohibited in sport under the WADA list, and a Norwegian doping laboratory found that a product sold as CJC-1295 was in fact the 29-residue amidated peptide without the DAC (usually called Mod GRF 1-29); the weekly milligram schedules that circulate online are extrapolations from the weight-based trial doses rather than tested regimens.
What researchers are exploring
These themes organize the educational information currently available. Individual claims remain under source review and are not treatment claims.
- 1
Growth Hormone Studies
Preclinical evidence and hormone dynamics
- 2
Fertility Research
Exploring reproductive applications
- 3
Summary
Key takeaways and research considerations
What is known and what still needs verification
Available context is organized without assigning unsupported study models or evidence grades.
- Not graded
Growth Hormone Studies
Preclinical evidence and hormone dynamics
- Not graded
Fertility Research
Exploring reproductive applications
Amounts recorded for CJC-1295 DAC
These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.
- 1Dose Strategy A · lower endpointSign in for schedule, duration and source context.200 mcg
- 2Dose Strategy A · upper endpointSign in for schedule, duration and source context.400 mcg
- 3Total Weekly Range · lower endpointSign in for schedule, duration and source context.1 mg
Chemistry identifiers
Sequence, synonyms and registry identifiers as recorded in PubChem, the National Library of Medicine's open chemistry database. Formula, mass and CAS number are summarized at the top of the page.
Sequence
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(N-epsilon-3-maleimidopropionyl)-NH2
Also listed as
CJC 1295, CJC-1295, GRF 1-29 (CJC1295), DAC:GRF (ConjuChem development name), UNII 62RC32V9N7, DTXSID501027567, RefChem:918751, CJC1295
InChIKey
ZUQGTWKGESAQCD-ZGFIGYLBSA-N
IUPAC name
(3S)-4-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-6-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-4-oxobutanoic acid
Limitations and unknowns
Sources
1 link carried over from the earlier page, awaiting verification.